Zydus Lifesciences completes purchase of Sterling Biotech API business
Zydus Lifesciences told the National Stock Exchange it has completed buying the API business of Sterling Biotech, recording Rs 167 crore as the amount of the transaction completed.
Key points
- Zydus Lifesciences said in a filing with the National Stock Exchange that it has completed buying Sterling Biotech's API business.
- The filing records Rs 167 crore as the amount completed and 2 November 2026 as the completion date; the board-approved consideration was Rs 840 million (Rs 84 crore).
- The filing does not say how the deal will affect the company's revenue or profit, and does not explain the gap between the two amounts.
Photo: Wikimedia Commons, CC0 1.0 (cropped). Representational image.
Zydus Lifesciences Limited said in a filing with the National Stock Exchange on 2 November 2026 that it has completed its acquisition of the active pharmaceutical ingredients (API) business of Sterling Biotech Limited. The filing records the amount of the transaction completed as Rs 167 crore and the percentage completed as 100%. The company describes the filing as an update to its earlier announcements on the deal.
What Happened
In its filing, the company recalled that it had told the exchange on 23 August 2024 that, through a wholly owned subsidiary, it had acquired a 50% stake in Sterling Biotech Limited. While buying that stake, the company said, it negotiated the right to acquire Sterling Biotech's API business at a pre-defined value, and it has exercised that right.
The filing says the company's Board of Directors approved a Business Transfer Agreement on 17 September 2024 to buy the API business on a going-concern basis. This is a slump sale, meaning the business is bought as a whole, without values assigned to individual assets and liabilities, on a cash-free and debt-free basis. The pre-defined lump-sum consideration was Rs 840 million, which is Rs 84 crore, subject to conditions precedent and closing-date adjustments set out in the agreement.
The business consists of a portfolio of fermentation-based API products: Lovastatin, Daunorubicin, Doxorubicin and Epirubicin. It has a manufacturing facility at Masar, near Vadodara in Gujarat, which the company says is close to its existing facility at Dabhasa.
The update gives the reason as "Transaction Completed". It records 2 November 2026 as the date the transaction was completed and Rs 167 crore as the amount of the transaction completed. The filing does not explain how this amount relates to the pre-defined consideration of Rs 84 crore.
What It Means
For readers who follow the company, the filing confirms that a deal approved by its board in September 2024 has now closed. The company said in the filing that the API business is a strategic fit because of its fermentation-based product portfolio and the Masar facility, and that it meets the company's strategic and commercial objectives.
The filing does not say how the acquisition will affect the company's revenue or profit, and this report does not estimate any effect. Any financial impact would have to come from the company's own later disclosures to the exchange.
Oquilia Data: Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE)
| Close, 30 Oct 2026 | Rs 1,245.50 (+5.16% on the day) |
|---|---|
| Return 1M / 3M / 6M / YTD / 1Y | +7.19% / +11.69% / +39.65% / +36.22% / +26.30% |
| Against Nifty 50, 1M / 3M / YTD | +5.27 / +16.89 / +47.99 points |
| 52-week closing high / low | Rs 1,245.50 (30 Oct 2026) / Rs 860.60 (23 Mar 2026) |
| Turnover, 20-session average | Rs 152.24 cr; 51.4% delivered; latest volume 2.7x |
| Insider trades, 90 days | none by promoters, directors or KMP |
Closes adjusted for splits and bonuses; returns exclude dividends; insider figures from BSE filings. Facts from NSE's files, not investment advice.
Full record: Zydus Lifesciences share price on Oquilia
Source: Company filing on NSE
Sources & Citations
- Company filing on NSE — National Stock Exchange of India